Individually, Cipla, Gland Pharma, JB Chemicals and Pharmaceuticals, Max Healthcare, Neuland Laboratories and Apollo Hospital Enterprises hit their respective record highs today. Menawhile, Sun Pharmaceutical Industries, Cadila Healthcare, Glenmark Pharmaceuticals, Panacea Biotech and RPG Lifesicenes are among those that hit 52-week highs in the intra-day trade today.
Investors rushed to buy pharma stocks as the Indian government will open up vaccination to anyone over 18 years of age starting May 1 with greater flexibility on pricing, procurement and administration of vaccines. This opens up the private market for vaccination and provides more leeway to states and private companies.
"Better realisation in the private market along with reports of funding from the government for capacity expansion (Rs 3,000 crore/Rs 1,500 crore credit line for Serum Institute/Bharat Biotech) could have potential to spur vaccine production at a time when demand may spike with this eligibility relaxation," analysts at CLSA said in healthcare sector outlook report dated April 20.
For those at Axis Capital, the sudden spurt in Covid-related drugs will benefit players like Cipla, Dr Reddy’s, and Cadila who are scaling up capacity and production to meet the sudden rise in demand.
"The government measures to control the spread include approval of vaccines (which are still under trials) for emergency use – earlier Covaxin and now Sputnik-V by DRL/RDIF; ZyCovd by Cadila (in phase 3) expected by May. However, government procurement (at USD 2 per dose) and distribution is making it unviable for players to scale up production, given high costs/ investments in facilities, transportation and storage," the brokerage firm said. However, it expects 8-10 per cent growth for Indian Pharma Market (IPM) in FY22 (on lower FY21 base), but if Covid situation persists we could see a muted trend – similar to FY21.
At 01:50 pm, the S&P BSE Healthcare index (up 2 per cent at 23,570) and Nifty Pharma index (2 per cent at 13,522) were outperforming the benchmark indices, S&P BSE Sensex and Nifty50, which were up 0.16 per cent each. RPG Lifesciences, Vivimed Labs, Morepen Laboratories, Nectar Lifesciences, Wockhardt and Panacea Biotech were up in the range of 10 per cent to 20 per cent.
COMPANY | LATEST | PREV CLOSE | GAIN(%) |
RPG LifeScience. | 479.10 | 399.25 | 20.0 |
Morepen Labs. | 44.00 | 37.20 | 18.3 |
Wockhardt | 521.05 | 457.30 | 13.9 |
Panacea Biotec | 294.30 | 267.55 | 10.0 |
Bliss GVS Pharma | 101.80 | 92.55 | 10.0 |
Marksans Pharma | 58.10 | 53.40 | 8.8 |
Dishman Carbogen | 143.35 | 132.50 | 8.2 |
Astrazeneca Phar | 3,884.45 | 3,590.75 | 8.2 |
Take Solutions | 49.10 | 45.40 | 8.2 |
Suven Life Scie. | 91.70 | 84.90 | 8.0 |
Shilpa Medicare | 408.00 | 377.95 | 8.0 |
Gufic BioScience | 124.60 | 115.45 | 7.9 |
Indrapr.Medical | 58.25 | 54.55 | 6.8 |
IOL Chemicals | 601.90 | 564.50 | 6.6 |
Fortis Health. | 213.55 | 200.50 | 6.5 |
SPARC | 169.35 | 159.70 | 6.0 |
Pfizer | 5,598.85 | 5,328.30 | 5.1 |
Cadila Health. | 553.00 | 527.30 | 4.9 |
Dr Reddy's Labs | 5,195.30 | 4,970.55 | 4.5 |
Fermenta Biotec. | 314.05 | 301.60 | 4.1 |
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
-
Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
-
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in